Vitruvia Medical AG, CH0461931419

Vitruvia Medical AG / CH0461931419

25.07.2024 - 21:58:27

Vitruvia Medical AG: Half yearly results as per June 30th, 2024

EQS-Ad-hoc: Vitruvia Medical AG / Key word(s): Half Year Results/Half Year Results


25-Jul-2024 / 21:58 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Vitruvia Medical AG half-year results as of June 30, 2024   Vitruvia Medical AG achieves results as expected in the first half of 2024. The Board of Directors confirms the forecast for the year as a whole. Vitruvia Medical AG is on target for the first six months of 2024. The result amounted to CHF -52,968.06 compared to CHF -150,464.24 in the previous year. Based on the expected results for the first half of 2024, the company's management confirms the outlook for the current full year. For this period, the Board of Directors expects consolidated sales of around EUR 2.0 million. On a consolidated basis, Vitruvia Medical AG anticipates a further improvement in earnings compared to the previous year.  


End of Inside Information

25-Jul-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English
Company: Vitruvia Medical AG
Kesselackerstr. 18
5611 Anglikon
Switzerland
Phone: +41 44 915 33 78
E-mail: kontakt@vitruvia-med.com
Internet: www.vitruvia-med.com
ISIN: CH0461931419
WKN: A2PDWF
Listed: Regulated Unofficial Market in Munich
EQS News ID: 1954611

 
End of Announcement EQS News Service

1954611  25-Jul-2024 CET/CEST
fncls.ssp?fn=show_t_gif&application_id=1954611&application_name=news&site_id=trading_house_net~~~7efceac5-959a-43d6-afef-21ad42b6a5d4
@ dgap.de